ProfileGDS5678 / 1446690_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 24% 24% 24% 23% 23% 24% 23% 23% 23% 23% 23% 23% 23% 23% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.588324
GSM967853U87-EV human glioblastoma xenograft - Control 22.5481124
GSM967854U87-EV human glioblastoma xenograft - Control 32.5509724
GSM967855U87-EV human glioblastoma xenograft - Control 42.4846423
GSM967856U87-EV human glioblastoma xenograft - Control 52.4929523
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6204124
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.5821223
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.5258223
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.5057623
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.5322423
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.5323923
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.5095523
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.5402923
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.5388823